Gamma Biosciences, a company founded by KKR, has announced that it has reached an agreement with Merck. Under the terms of the agreement, Merck will acquire Gamma's operating company, Mirus Bio, for $600 million in cash.

Mirus Bio is a leading provider of innovative transfection solutions used for the delivery of genetic material into cells.

Gamma acquired a majority stake in Mirus Bio in 2021 and has been working closely with the company to support its growth.

' Over the past few years, we've had the pleasure of supporting Dale and the Mirus team as they worked to make these best-in-class transfection products available to developers of cell and gene therapies, while maintaining the company's long-standing commitment to the research community', said Matt Gunnison, CEO of Gamma Biosciences.

Dale Gordon, President and CEO of Mirus Bio, added: 'With the support of Gamma Biosciences and KKR, we have commercialized our scalable GMP delivery platforms for clinical use and significantly strengthened our position in the cell and gene therapy market.

Copyright (c) 2024 CercleFinance.com. All rights reserved.